AMRI Announces Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Albany Molecular Research (AMRI) Tops Q3 EPS by 1c
November 5, 2015 7:19 AM ESTAlbany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.14, $0.01 better than the analyst estimate of $0.13. Revenue for the quarter came in at $101.4 million versus the consensus estimate of $95.15 million.
Albany Molecular Research reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
... More